Вазопротекция и нефропротекция: звенья одной цепи
Аннотация
За последние годы микроальбуминурия (МАУ) эволюционировала от индикатора дисфункции почечных артерий до маркера системной дисфункции эндотелия, отражающего риск развития неблагоприятных сердечно-сосудистых событий. МАУ также служит достоверным маркером поражения и сосудистых бассейнов, таких как сосуды почек, конечностей, аорты, мозга. Поэтому первичная и вторичная профилактика МАУ, осуществляемая с помощью ингибирования эффектов ангиотензина II, а зачастую, с помощью комбинированной терапии, является одной из важнейших целей нефро-, кардиои вазопротекции.
Об авторах
Н. Ш. Загидуллин
ГОУ ВПО “Башкирский государственный медицинский университет Росздрава”
Россия
Россия
Ассистент кафедры
Уфа
Ш. З. Загидуллин
ГОУ ВПО “Башкирский государственный медицинский университет Росздрава”
Россия
Россия
Заведующий кафедрой пропедевтики внутренних болезней
Уфа
К. Ф. Валеева
ГОУ ВПО “Башкирский государственный медицинский университет Росздрава”
Россия
Россия
Интерн кафедры
Уфа
Список литературы
1. Schmieder RE, Schrader J, Zidek W, et al. Low-grade albuminuria and cardiovascular risk. What is the evidence? Clin Res Cardiol 2007; 96: 247-57.
2. Brownlee M, Cerami A, Vlassara H. Advanced products of nonenzymatic glycosylation and the pathogenesis of diabetic vascular disease. Diabetes Metab Rev 1988; 4: 437-51.
3. Lakatta EG, Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises. Part I: aging arteries: a ‘‘set up’’ for vascular disease. Circulation 2003; 107: 139-46.
4. Jensen JS. Renal and systemic transvascular albumin leakage in severe atherosclerosis. Arterioscler Thromb Vasc Biol 1995; 15: 1324-9.
5. Yuyun MF, Khaw KT, Luben R, et al. A prospective study of microalbuminuria and incident coronary heart disease and its prognostic significance in a British population: the EPICNorfolk study. Am J Epidemiol 2004; 159: 284-93.
6. Rossi MC, Nicolucci A, Pellegrini F, et al. Identifying patients with type 2 diabetes at high risk of microalbuminuria: results of the DEMAND (Developing Education on Microalbuminuria for Awareness of reNal and cardiovascular risk in Diabetes) Study. Nephrol Dial Transplant 2008; 23: 1278-84.
7. Garg AX, Kiberd BA, Clark WF et al. Albuminuria and renal insufficiency prevalence guides population screening: results from the NHANES III. Kidney Int 2002; 61: 2165-75.
8. Kanaya AM, Barrett-Connor E, Gildengorin G, Yaffe K. Change in cognitive function by glucose tolerance status in older adults: a 4-year prospective study of the Rancho Bernardo study cohort. Arch Intern Med 2004; 164: 132733.
9. Gerstein HC, Mann JF, Yi Q, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286: 421-6.
10. Schalkwijk CG, Stehouwer CD. Vascular complications in diabetes mellitus: the role of endothelial dysfunction. Clin Sci (Lond) 2005; 109(2): 143-59.
11. Schalkwijk CG, Poland DC, van Dijk W et al. Plasma concentration of C-reactive protein is increased in type I diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation. Diabetologia 1999; 42: 351-7.
12. Stehouwer CD, Fischer HR, van Kuijk AW et al. Endothelial dysfunction precedes development of microalbuminuria in IDDM. Diabetes 1995; 44: 561-4.
13. Nilsson TK, Hellsten G, Amiral J. Plasma thrombomodulin concentrations in relation to cardiovascular risk factors in a population sample. Blood Coagul Fibrinolysis 1993; 4: 4558.
14. Inukai T, Fujiwara Y, Tayama K et al. Clinical significance of measurements of urinary and serum thrombomodulins in patients with non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 1996; 33: 99-104.
15. Lin J., Glynn R.J., Rifai N. et al. Inflammation and Progressive Nephropathy in Type 1 Diabetes in the Diabetes Control and Complications Trial. Diabetes Care 2008; 31: 2338-43.
16. Rathke CN, Persson F, Tarnow L, et al. YKL-40, a Marker of Inflammation and Endothelial Dysfunction, Is Elevated in Patients With Type 1 Diabetes and Increases With Levels of Albuminuria. Diabetes Care 2009; 32: 323-8.
17. Simonsen U, Christensen FH, Buus NH. The effect of tempol on endothelium-dependent vasodilatation and blood pressure. Pharmacology & Therapeutics 2009; 122: 109-24.
18. Corretti MC, Anderson TJ, Benjamin EJ, et al. International Brachial Artery Reactivity Task Force. Guidelines for the ultrasound assessment of endothelial-dependent flowmediated vasodilation of the brachial artery: a report of the international brachial artery reactivity task force. JACC 2002; 39: 257-65.
19. Narayanan IV, Jacobs JrDR, Duprez D, et al. Association between Endothelial Biomarkers and Arterial Elasticity in Young Adults – The CARDIA Study. J Am Soc Hypertens 2008; 2(2): 70-9.
20. Temelkova-Kurkitschiev TS, Koehler C, Henkel E, et al. Post-challenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level. Diabetes Care 2000; 23: 1830-4.
21. MykkanenL,ZaccaroDJ,O’LearyDH,etal.Microalbuminuria and carotid artery intima-media thickness in nondiabetic and NIDDM subjects. Stroke 1997; 28: 1710-6.
22. Mule G, Cottone S, Vadala A, et al. Relationship between albumin excretion rate and aortic stiffness in untreated essential hypertensive patients. J Intern Med 2004; 256(1): 22-9.
23. Abbatecola AM, Barbieri M, Rizzo MR, et al. Arterial Stiffness and Cognition in Elderly Persons With Impaired Glucose Tolerance and Microalbuminuria 2008; 63A: 9: 9916.
24. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, et al. Albuminuria – a marker of renal and Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia 1989; 32(10): 766-7.
25. Liu JE, Robbins DC, Palmieri V, et al. Association of albuminuria with systolic and diastolic left ventricular dysfunction in type 2 diabetes: the Strong Heart Study. JACC 2003; 41: 2022-8.
26. Wachtell K, Olsen MH, Dahlof B, et al. Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. J Hypertens 2002; 20: 405-12. What is the evidence? Clin Res Cardiol 2007; 96: 247-57.
27. Odili AN. Prevalemce and clinical correlatesof microalbuminuria in newly diagnosed hypertensive subjects. Niger J Med 2008; 17(4): 452-6.
28. Naess IA, Christiansen SC, Romundstad P, et al. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 2007; 5(4): 692-9.
29. Mahmoodi BK, Gansevoort RT, Nic JG, et al. Thromboembolism Microalbuminuria and Risk of Venous JAMA 2009; 301(17): 1790-7.
30. Hillege HL, Janssen WM, Bak AA, et al. PREVEND Study Group. Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. J Intern Med 2001; 249(6): 519-26.
31. The Diabetes Control and Complications (DCCT) Research Group. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int 1995; 47: 1703-20.
32. Ritz E. Albuminuria and vascular damage– the vicious twins. N Engl J Med 2003; 348: 2349-52.
33. Gansevoort RT, de Jong PE. The case for using albuminuria in staging chronic kidney disease. J Am Soc Nephrol 2009; 20(3): 465-8.
34. Remuzzi G, Ruggenenti P, Benigni A. Understanding the nature of renal disease progression. Kidney Int 1997; 51: 2-15.
35. Ljungman S, Wikstrand J, Hartford M, Berglund G. Urinary albumin excretion – a predictor of risk of cardiovascular disease. A prospective 10-year follow-up of middle-aged nondiabetic normal and hypertensive men. Am J Hypertens 1996; 9: 770-8.
36. Kaplan N.M. Management of hypertension in patients with type 2 diabetes mellitus: guidelines based on current evidence. Ann Intern Med 2001; 135: 1079-83.
37. Viberti G, Mogensen CE, Groop LC, Pauls JF. Effect of captopril on progression to clinical proteinuria in patients with insulindependent diabetic patients and microalbuminuria. JAMA 1994; 271: 275-9.
38. Ravid M, Lang R, Rachmani R, Linshner M. Long-term renoprotective effect of angiotensin converting enzyme inhibition in non-insulin dependent diabetes mellitus. Arch Intern Med 1996; 156: 286-9.
39. Lewis EJ, Hunsicker LG, Bain RF, Rohde RD. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-62.
40. HeartOutcomesPreventionEvaluation(HOPE)StudyInvestigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes melllitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-9.
41. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 85160.
42. Fioretto P, Frigato F, Velussi M, et al. Effects of angiotensin converting enzyme inhibitors and calcium antagonists on atrial natriuretic peptide release and action on albumin excretion rate in hypertensive insulindependent diabetic patients. Am J Hypertens 1992; 5: 837-46.
43. Bakris GL, Weir MR, De Quattro V, McMahon FG. Effects of an ACE inhibitor/calcium channel antagonist combination on proteinuria in diabetic nephropathy. Kidney Int 1998; 54: 1283-9.
44. Brown S, Walton C, Crawford P, Bakris GL. Long-term effects of antihypertensive regimens on renal hemodynamics and proteinuria. Kidney Int 1993; 43: 1210-8.
45. Munter K, Hergenroder S, Jochims K, Kirchengast M. Individual and combined effects of verapamil or trandolapril on attenuating hypertensive glomerulopathic changes in the stroke-prone rat. J Am Soc Nephrol 1996; 7: 681-6.
46. Bakris GL, Barnhill BW, Sadler R. Treatment of arterial hypertension in diabetic humans: importance of therapeutic selection. Kidney Int 1992; 41: 912-9.
47. Bohlen L, de Court Weidmann P. Comparative study of the effect of ACE inhibitorsand other antihypertensive agents on proteinuria in diabetic patients. Am J Hypertens 1994; 7: 84S-92.
48. Remuzzi G., Macia M., Ruggenanti P. Impact of the blood pressure control and agiotensin-converting enzyme inhibitor therapy on new-onset microalbminuria in type 2 diabetes: a post hoc analysis of the BENEDIKT trial. J Am Soc Nephrol 2006; 17(12): 3472-81.
49. Rubio-Guerra AF, Arceo-Navarro A, Vargas-Ayala G, et al. The effect of trandolapril and its fixed-dose combination with verapamil on proteinuria in normotensive adults with type 2 diabetes. Diabetes Care 2004; 27(7): 1688-91.
50. Остроумова О.Д., Жукова О.В., Абакумов Ю.Е. и др. Эффективность и безопасность применения комбинированного препарата трандолаприл/верапамил в качестве стартовой терапии у пациентов с артериальной гипертензией и утолщением комплекса интима-медиа сонных артерий. Кардиология 2008; 11: 36-41.
51. Parving HH. Excess mortality associated with diuretic therapy in diabetes mellitus. Arch Intern Med 1992; 152: 1093-4.
52. Небиеридзе Д.В. Комбинированная терапия артериальной гипертонии: фокус на плейотропные эффекты. Кардиоваскулярная тепаия и профилактика; 2007; 6(4); 96-99.
Рецензия
Для цитирования:
Загидуллин Н.Ш., Загидуллин Ш.З., Валеева К.Ф. Вазопротекция и нефропротекция: звенья одной цепи. Кардиоваскулярная терапия и профилактика. 2009;8(7):114-120.
For citation:
Zagidullin N.Sh., Zagidullin Sh.Z., Valeeva K.F. Vasoprotection and nephroprotection: links of the same chain. Cardiovascular Therapy and Prevention. 2009;8(7):114-120. (In Russ.)
Просмотров:
1238
Послать статью по эл. почте 
